Stephen V Liu reflects on OS from PACIFIC-R

Stephen V Liu shared the following insight on X:

“OS from PACIFIC-R: real-world outcomes with durvalumab (EAP) after chemoradiation for stage III NSCLC (n=1154). 3-year OS rate is 63.2% (median OS not reached) with better 3-year OS for PDL1+ (67% vs 54.4%) and concurrent vs sequential (64.8% vs 57.9%).”

Read further
Source: Stephen V Liu/X

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.